Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
22 Maggio 2024 - 3:05PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for precision oncology, announced today that two podium
presentations and multiple posters featuring data for the company’s
NeXT Personal® whole genome-based, tumor-informed assay for
ultra-sensitive ctDNA detection will be presented at the 2024
American Society of Clinical Oncology (ASCO) Annual Meeting, which
convenes from May 31-June 4, 2024, in Chicago, Illinois.
“As the body of studies continues to grow that demonstrates the
role our ultra-sensitive MRD test, NeXT Personal, can play in
identifying recurrent cancer early, we were honored to learn that
two Personalis studies were selected as podium presentations at
ASCO 2024’s Clinical Science Symposium”, said Dr. Richard Chen,
Chief Medical Officer and Executive Vice President, R&D at
Personalis.
The two studies that were selected to appear as podium
presentations are:
- Clinical Science Symposium: Emerging Role of ctDNA in
Breast Cancer
- Presenter: Isaac Garcia-Murillas, PhD
- Overview: Ultra-sensitive ctDNA mutation tracking to identify
molecular residual disease and predict relapse in patients with
early breast cancer.
- Abstract Number: 1010
- Clinical Science Symposium: Hitting the Mark - The
Ongoing Search for Immunotherapy Biomarkers
- Presenter: Rodrigo A Toledo, PhD, MBA
- Overview: Prognostic and predictive value of ultrasensitive
ctDNA monitoring in a metastatic pan-cancer cohort treated with
immune checkpoint inhibitors in the context of phase 1 clinical
trials.
- Abstract Number: 2510
Details of the Personalis abstracts are outlined below, and
further details about the poster presentations can be found
here.
- Abstract Title: Emerging Role of ctDNA in Breast
Cancer
- Presenter: Andrew B. Nixon PhD, MBA
- Overview: Ultra-sensitive ctDNA dynamics to capture therapy
response in pembrolizumab-treated gastroesophageal cancer.
- Abstract Number: 4025
- Abstract Title: Breast
Cancer—Local/Regional/Adjuvant
- Presenter: Adrienne Gropper Waks, MD
- Overview: Prevalence and dynamics of circulating tumor DNA
(ctDNA) among patients (pts) with HER2+ breast cancer (BC)
receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in
the DAPHNe trial.
- Abstract Number: 588
- Publication Title: Gastrointestinal Cancer—Colorectal
and Anal
- First Author: Joao Paulo Solar Vasconcelos, MD
- Overview: Circulating tumor DNA (ctDNA) kinetics in colorectal
cancer (CRC) treated with curative intent in the VICTORI study with
an ultrasensitive MRD assay.
- Abstract Number: e15625
About Personalis, Inc.
At Personalis, we are transforming the active management of
cancer through breakthrough personalized testing. We aim to drive a
new paradigm for cancer management, guiding care from biopsy
through the life of the patient. Our highly sensitive assays
combine tumor-and-normal profiling with proprietary algorithms to
deliver advanced insights even as cancer evolves over time. Our
products are designed to detect minimal residual disease (MRD) and
recurrence at the earliest time points, enable the selection of
targeted therapies based on ultra-comprehensive genomic profiling,
and enhance biomarker strategy for drug development. Personalis is
based in Fremont, California. To learn more, visit
www.personalis.com and connect with us on LinkedIn and X
(Twitter).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the NeXT Personal assay, the potential for NeXT Personal to
identify recurrent cancer early, or other future events. Such
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from any
anticipated results or expectations expressed or implied by such
statements. Factors that could materially affect actual results can
be found in Personalis’ filings with the U.S. Securities and
Exchange Commission, including Personalis’ most recent reports on
Forms 8-K, 10-K and 10-Q, and include those listed under the
caption “Risk Factors.” Personalis disclaims any obligation to
update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522193620/en/
Investors: Caroline Corner investors@personalis.com
415-202-5678
Media: pr@personalis.com
Grafico Azioni Personalis (NASDAQ:PSNL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Personalis (NASDAQ:PSNL)
Storico
Da Dic 2023 a Dic 2024